Equity Overview
Price & Market Data
Price: $1.51
Daily Change: +$0.14 / 9.27%
Daily Range: $1.32 - $1.60
Market Cap: $7,918,407
Daily Volume: 199,854
Performance Metrics
1 Week: -6.45%
1 Month: -28.57%
3 Months: 16.00%
6 Months: -45.90%
1 Year: -56.94%
YTD: -54.55%
Company Details
Employees: 6
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of Aramchol for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule for the treatment of non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study for HIV-associated lipodystrophy and non-alcoholic fatty liver disease. In addition, it develops products for cardiometabolic indications. The company has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with Virginia Commonwealth University to investigate the effect of adding Aramchol to prevent drug resistance to standard-of-care oncology agents in the treatment of hepatoma, cholangiocarcinoma, and colorectal cancer. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.